Malaria
Conditions
Keywords
Artesunate, Infant
Brief summary
This is essentially a laboratory study that is an addendum to an ongoing prospective Phase 4 multicenter observational study titled: Safety and Efficacy of Artesunate in Pregnant Women and Infants (ARTEMUM) being conducted in France. Infants, the parents of whom provided consent to have data collected from their child as part of the ARTEMUM study, will have an additional blood sample collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous (IV) artesunate treatment. A maximum of 4 samples will be taken and plasma will be isolated and stored frozen until analysis for plasma artesunate and dihydroartemisinin (DHA) concentrations. Red blood cells will also be frozen for further analysis (for example Kelch-13 mutations). In addition, a standard of care blood sample will be collected approximately one month post treatment for clinical laboratory tests.
Detailed description
This is essentially a laboratory study that is an addendum to an ongoing prospective Phase 4 multicenter observational study titled: Safety and Efficacy of Artesunate in Pregnant Women and Infants (ARTEMUM) being conducted in France. Parents of infants under 2 years of age who provided consent to participate in the ARTEMUM study will be asked to provide consent for their child to this laboratory study providing the infant was eligible for the ARTEMUM study. During the first 48 hours after the start of IV artesunate treatment, a maximum of 4 samples of blood will be collected when other standard of care samples are being collected. With regard to blood collected for standard of care, it is recognized that samples between 0.25 and 5 hours post doses will be the most useful for pharmacokinetic (PK) analysis due to the 30-to-45-minute half-life of DHA. Plasma will be isolated and frozen until submission to the central laboratory for artesunate and DHA plasma concentrations. In addition, a standard of care blood sample will be collected approximately one month post treatment for clinical laboratory tests. The recommendation by the World Health Organization (WHO) is followed in France not only for safety (anemia) but also for relapse. Clinical laboratory test results and other data to be included in the analysis will be abstracted from the case report forms (CRFs) from the ARTEMUM study.
Interventions
Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
Sponsors
Amivas Inc.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Minutes to 23 Months
Healthy volunteers
No
Inclusion criteria
* Parental consent provided to the ARTEMUM Study * Parental consent provided to participate in this PK Laboratory Study * Infants \< 2 years of age with malaria (positive blood by polymerase chain reaction (PCR) or thin or thick smear or rapid diagnostic test (RDT), or any combination of those) treated by at least 1 dose of intravenous artesunate
Exclusion criteria
* Hemoglobin \< 7.0 g/dL at the time when additional blood sample for PK assessment will be drawn as part of standard of care
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in concentration of artesunate in blood plasma samples | Approximately at 5 minutes, 30 minutes, 90 minutes, and 4 hours after artesunate intravenous injection | Change in concentration of artesunate in blood plasma samples collected as part of standard of care |
| Change in concentration of dihydroartemisinin in blood plasma samples | Approximately at 5 minutes, 30 minutes, 90 minutes, and 4 hours after artesunate intravenous injection | Change in concentration of dihydroartemisinin in blood plasma samples collected as part of standard of care |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety, as measured by the number of participants with adverse events | During standard of care treatment with intravenous artesunate | Safety, as measured by the number of participants with adverse events |
| Tolerability, as measured by the number of doses of artesunate administered to each participant | During standard of care treatment with intravenous artesunate | Tolerability of artesunate treatment, as measured by the number of doses of artesunate administered to each participant |
Countries
France
Contacts
Primary ContactBernadette Tock
Outcome results
None listed